Dual targeting of BCL-2 and MCL-1 in the presence of BAX breaks venetoclax resistance in human small cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dual targeting of BCL-2 and MCL-1 in the presence of BAX breaks venetoclax resistance in human small cell lung cancer

Published:2023-03-14 Issue:10 Volume:128 Page:1850-1861
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Valko Zsuzsanna,Megyesfalvi Zsolt,Schwendenwein Anna,Lang Christian,Paku Sandor,Barany Nandor,Ferencz Bence,Horvath-Rozsas Anita,Kovacs Ildiko,Schlegl Erzsebet,Pozonec Veronika,Boettiger Kristiina,Rezeli Melinda,Marko-Varga Gyorgy,Renyi-Vamos Ferenc,Hoda Mir Alireza,Klikovits Thomas,Hoetzenecker Konrad,Grusch Michael^ORCID,Laszlo Viktoria,Dome Balazs^ORCID,Schelch Karin^ORCID

Funder

Nemzeti Kutatási, Fejlesztési és Innovációs Hivatal

Ministry for Innovation and Technology of Hungary, Hungarian Respiratory Society

Fru Berta Kamprads Stiftelse

Berndorf Private Foundation

Austrian Science Fund

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://www.nature.com/articles/s41416-023-02219-9.pdf

Reference53 articles.

1. Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 2017;17:725–37.

2. Schwendenwein A, Megyesfalvi Z, Barany N, Valko Z, Bugyik E, Lang C, et al. Molecular profiles of small cell lung cancer subtypes: therapeutic implications. Mol Ther Oncolytics. 2021;20:470–83.

3. Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Prim. 2021;7:3.

4. Kahnert K, Kauffmann-Guerrero D, Huber RM. SCLC-state of the art and what does the future have in store? Clin Lung Cancer. 2016;17:325–33.

5. Karachaliou N, Pilotto S, Lazzari C, Bria E, de Marinis F, Rosell R. Cellular and molecular biology of small cell lung cancer: an overview. Transl Lung Cancer Res. 2016;5:2–15.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive genomic and spatial immune infiltration analysis of survival outliers in extensive-stage small cell lung cancer receiving first-line chemoimmunotherapy;International Immunopharmacology;2024-11

2. Apoptosis-induced treatment for ovarian cancer from self-assembled nanocomposites of Fe3O4 nanoparticles and porous organic cages;Colloids and Surfaces A: Physicochemical and Engineering Aspects;2024-08

3. Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer;Nature Reviews Clinical Oncology;2024-07-04

4. Capivasertib reverses chemotherapy-induced esophageal cancer resistance via inhibiting Akt-associated Mcl-1 upregulation;Heliyon;2024-07

5. Extraction, Quantification and Anti-Cancer Activity of Important Secondary Metabolite “Shatavarin-IV” from in vitro Callus Culture of Asparagus racemosus Willd.;Pharmacognosy Research;2024-06-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3